Agile Therapeutics, Inc. (AGRX) Stock Analysis

Agile Therapeutics, Inc. (AGRX) Healthcare & Pipeline Overview

Agile Therapeutics, Inc. is a women's healthcare company specializing in prescription contraceptive products, primarily the Twirla patch. With a focus on innovation and addressing unmet needs, Agile is developing line extensions to offer women more choices in managing their reproductive health within the specialty and generic drug market.

What Is the Investment Thesis for AGRX?

Agile Therapeutics presents a focused investment opportunity within the women's healthcare sector, centered on its Twirla contraceptive patch and pipeline of line extensions. The company's gross margin of 54.2% indicates potential profitability as sales scale. Growth catalysts include successful commercialization of Twirla and positive clinical trial results for its pipeline products like AG200-15 ER and SmP. However, potential risks include competition from established contraceptive methods, regulatory hurdles, and the need for additional financing, given the company's negative profit margin of -73.8%. The company's beta of 1.58 suggests higher volatility compared to the market.

Based on FMP financials and quantitative analysis

AGRX Key Highlights

Market capitalization of $10.4M indicates a small-cap company with potential for growth but also higher risk.

• Gross margin of 54.2% suggests a strong pricing power and efficient cost management in producing Twirla.
• Profit margin of -73.8% highlights the company's current unprofitability, requiring close monitoring of operating expenses and revenue growth.
• Beta of 1.58 indicates higher volatility compared to the overall market, potentially offering higher returns but also greater risk.
• Lead product Twirla offers a differentiated contraceptive option in the form of a once-weekly patch.

Who Are AGRX's Competitors?

AGRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AGRX's Key Strengths?

Innovative transdermal patch technology.

• Focus on women's health and contraception.
• Pipeline of line extensions.
• Established brand with Twirla.

What Are AGRX's Weaknesses?

Limited product portfolio.

• Reliance on Twirla sales.
• Negative profit margin.
• Small market capitalization.

What Could Drive AGRX Stock Higher?

Potential FDA approval of Twirla line extensions (AG200-15 ER, SmP).

• Expansion of Twirla sales and market share.
• Strategic partnerships to expand geographic reach.

What Are the Key Risks for AGRX?

Financial-distress signal — its Altman Z-Score of -41.24 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established contraceptive methods.
• Regulatory setbacks for pipeline products.
• Need for additional financing.
• Product liability risks.

What Are the Growth Opportunities for AGRX?

• Expansion of Twirla Market Share: Agile has the opportunity to increase Twirla's market share within the U.S. contraceptive market. This can be achieved through targeted marketing campaigns, improved patient education, and strategic partnerships with healthcare providers. The U.S. contraceptive market is estimated to be worth billions of dollars annually, providing a significant opportunity for Agile to grow its revenue base. Timeline: Ongoing.
• Successful Development and Commercialization of Pipeline Products: Agile's pipeline of Twirla line extensions, including AG200-15 ER and SmP, represents a significant growth opportunity. Positive clinical trial results and successful commercialization of these products could expand Agile's product portfolio and address a wider range of patient needs. The market for extended-cycle and low-dose contraceptives is growing, driven by patient demand for more convenient and personalized options. Timeline: 2027-2029.
• Strategic Partnerships and Licensing Agreements: Agile can pursue strategic partnerships and licensing agreements to expand its geographic reach and product offerings. Collaborating with larger pharmaceutical companies or regional distributors could accelerate the commercialization of Twirla and its pipeline products in international markets. Licensing agreements for complementary women's health products could also diversify Agile's revenue streams. Timeline: Ongoing.
• Focus on Patient Adherence and Compliance: Improving patient adherence and compliance with Twirla is crucial for driving sales growth. Agile can implement patient support programs, develop educational materials, and leverage digital health technologies to enhance patient engagement and adherence. Increased adherence leads to better contraceptive efficacy and higher customer retention rates. Timeline: Ongoing.
• Expansion into Adjacent Women's Health Markets: Agile can explore opportunities to expand into adjacent women's health markets, such as hormone therapy or fertility treatments. Leveraging its expertise in transdermal drug delivery and its existing relationships with healthcare providers, Agile can diversify its product portfolio and address a broader range of women's health needs. The women's health market is a large and growing market, offering numerous opportunities for Agile to expand its business. Timeline: 2030+

What Are AGRX's Competitive Advantages?

• Proprietary transdermal patch technology for drug delivery.
• Established brand recognition with Twirla.
• Pipeline of line extensions to expand product offerings.
• Relationships with healthcare providers and distributors.

What Does AGRX Do?

Agile Therapeutics, Inc., founded in 1997 and headquartered in Princeton, New Jersey, is a women's healthcare company dedicated to researching, developing, and commercializing innovative prescription contraceptive products. The company's flagship product is Twirla (AG200-15), a once-weekly transdermal patch that delivers a combination of ethinyl estradiol and levonorgestrel. Twirla provides women with a convenient and discreet method of contraception, offering an alternative to daily oral pills. Agile's mission is to expand contraceptive options and improve women's reproductive health outcomes. Beyond Twirla, Agile is actively developing a pipeline of line extensions, including AG200-15 Extended Regimen (ER), designed to reduce the frequency of withdrawal bleeding to four times per year. Other pipeline products include AG200-15 smaller patch (SmP) aimed at providing shorter, lighter withdrawal bleeds and potentially enhancing contraceptive efficacy, AG200-15 ER SmP combining extended regimen with a smaller patch, and P-Patch, a progestin-only contraceptive patch for women who cannot or prefer not to use estrogen-containing products. Agile operates primarily in the United States, focusing on commercializing and expanding the market reach of Twirla and its future product offerings.

What Products and Services Does AGRX Offer?

• Researches and develops prescription contraceptive products for women.
• Commercializes Twirla, a once-weekly contraceptive patch.
• Develops Twirla line extensions, including extended regimen and smaller patch variations.
• Aims to provide women with convenient and discreet contraceptive options.
• Focuses on addressing unmet needs in women's reproductive health.
• Seeks regulatory approvals for its products from the FDA.

How Does AGRX Make Money?

• Develops and manufactures prescription contraceptive products.
• Sells products directly to wholesalers and distributors.
• Generates revenue through product sales.
• Invests in research and development to expand its product pipeline.

What Industry Does AGRX Operate In?

Agile Therapeutics operates within the competitive specialty and generic drug manufacturing industry, specifically targeting the women's health market. The contraceptive market is characterized by diverse options, including oral pills, intrauterine devices (IUDs), implants, and transdermal patches like Twirla. The industry is influenced by factors such as evolving patient preferences, technological advancements, and regulatory changes. Agile competes with established pharmaceutical companies and generic manufacturers, requiring a focus on innovation, effective marketing, and strategic partnerships to gain market share. The demand for convenient and discreet contraceptive methods is a key market trend that Agile aims to capitalize on with its Twirla patch and pipeline products.

Who Are AGRX's Key Customers?

• Women seeking prescription contraception.
• Healthcare providers who prescribe contraceptive products.
• Wholesalers and distributors of pharmaceutical products.
• Pharmacies that dispense prescription medications.

Company Profile

Agile Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Alfred F. Altomari. AGRX has traded publicly since 2014.

Agile Therapeutics, Inc. Financial Trajectory

Agile Therapeutics, Inc. (AGRX) reported $5.6M in revenue for Q2 FY2024, a decline of 2.4% compared to the prior quarter. The company recorded a net loss of $11.9M, with diluted EPS of $-1.73.

How Agile Therapeutics, Inc. Is Valued

Agile Therapeutics, Inc. carries a market capitalization of $10.4M, placing it in the micro-cap category.

Return on equity for Agile Therapeutics, Inc. stands at 132.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -91.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.46 means current liabilities exceed short-term assets, a liquidity point worth watching.

Agile Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -41.24 places it in the distress zone, a signal of elevated financial risk.

Agile Therapeutics, Inc. has missed Wall Street's EPS estimate in 3 of its last 5 reported quarters — a mixed record worth weighing. Reported results have landed about 10.9% below estimates on average.

Wall Street analysts project Agile Therapeutics, Inc. revenue of about $66.3M for fiscal 2026, with EPS near $1.70.

The most recent 12 insider filings for Agile Therapeutics, Inc. break down as 12 sales and 0 purchases. On net that is roughly 82K shares disposed (about $124K), a signal worth weighing alongside the fundamentals.

AGRX Financials

AGRX Latest News

AGRX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources